Tag: Zymeworks

Zymeworks: A Sturdy Purchase Amidst Zanidatamab’s Promising Developments (NASDAQ:ZYME)

Per Fintel, brief curiosity stands at 3,256,501 shares, suggesting a average degree of investor skepticism or hedging exercise. Institutional possession is excessive at 93.05%, with important actions noticed: 32 new positions and...

Latest articles

spot_img

Sign up to receive news and updates

To be updated with all the latest news, offers and special announcements.

By signing up you agree to receive email newsletters, notifications and alerts from Covid Dark PRO. You can unsubscribe at any time.
WP2Social Auto Publish Powered By : XYZScripts.com